“Neuros Medical, with its patented Altius system high-frequency nerve block technology, has the opportunity to develop important therapy options for patients who experience significant pain as a result of a number of disease conditions,” Wilder said in prepared remarks. “The initial indication, for post-amputation pain, represents a compelling and urgent unmet medical need. I am delighted to join founder Jon Snyder, Zi-Ping Fang and the rest of the team, which has worked tirelessly to bring this technology into the clinic. We will pursue completion of the initial IDE pivotal clinical trial, eventual U.S. and international commercialization of this initial indication, as well other potential clinical applications. To accomplish this, we will supplement our Ohio-based technology center with an operational headquarters based in the San Francisco Bay Area.”
“Tom brings a proven track record and a wealth of directly relevant experience to Neuros,” added founder & chief business officer Jon Snyder. “He is passionate about developing novel treatments for physicians and their patients who have unmet clinical needs. We are delighted to have him aboard to lead the company through the next phases of growth and expansion.”
“Tom will bring enthusiasm, energy and his record of accomplishment to Neuros Medical,” chairman Alan Kaganov said in the statement. “We are extremely grateful to Jon Snyder for setting the vision of the Company, and elevating its status to a clinical stage Company. In the next few years, our investors expect that Tom will successfully guide the Altius system through clinical trials and ultimately, secure regulatory approval.”
Earlier this month, Neuros raised $20 million in what it’s calling a Series AA round, pledging the proceeds to a pivotal study of its Altius neurostimulation technology. Cleveland-based Neuros said the round was led by U.S. Venture Partners and included prior backers Boston Scientific (NYSE:BSX) and JumpStart plus contributions from Aperture Venture Partners and Osage University Partners.